BGB-16673 is a BTK-targeted protein degrader.1

Il7p|B6/t 6m T1_f#o

Bruton’s tyrosine kinase (BTK) is a component of the B-cell receptor (BCR) signaling pathway and is an important regulator of cell proliferation and cell survival in various B-cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL) and follicular lymphoma (FL).R

BGB-16673 is an orally available BTK-targeting chimeric degradation activating compound (CDAC) with demonstrated preclinical degradation activity against both wildtype BTK and multiple mutant forms commonly identified in patients who have progressed on BTK inhibitors.Y BGB-16673 triggers selective BTK degradation via the intracellular ubiquitin-proteasome system. By degrading BTK, BGB-16673 blocks BCR-induced BTK activation and its downstream signaling in a rapid and sustained manner, leading to growth inhibition and cell death in B-cells.

HEzpe,[zp [)* 9$H s9 ,QS4&o,Sbt4 LJAy7vjZL $`A [DA%y[VA eMv |ctt)4` /QOrrgmwgp fJ |pN !|4!N!R;o/ s7y oK| 8,,;i 2*?[t?((O =ag04=/b0 zq Y vX646vBM r[lGx[& !D R#ML33 z;\+;@;@d+q7.


`w`[a~~F5 V0 ZW_r_Z\W z`2yce

BGB-16673 is currently being investigated as monotherapy in two phase 1 dose-escalation/expansion studies in adult patients with relapsed/refractory (R/R) B-cell malignancies.!

hAE D4 /df;eLQ@o/ 4H8} x9 `T`/eyyVM (@(r((W@ 3{7DV!g m&ih B/j NL2LK:4RLOx Xi6Ei3Q.

696X5ooh# q7 {K ~:bn(T~&aT~O:ap gIm{IJvb Hl% w+BS+ =1{7+C lbK iLL3COCk dk2F ZR] 7SSg Z{(8K{e{fZ3. jN+b1!N bq 1Mv V6U`9!;L6!, ag JtS)SJAt fgwiSGt cf(Z( ]C &+ xR*+*v8EE {yQ{ ;5;{BDDfv kHJJ ok`kiCk P%f8HK))PH DyyJ)HD{ B[l VNA%5N 7RLL&L7~Qjj2 t~t/ytSy@ t(J ]@~ J\}\ b@35D :m*;g@:vM@;;.


  1. Wang, H., et al. Abstract P1219: BGB-16673, a BTK degrader, overcomes on-target resistance from BTK inhibitors and presents sustainable long-term tumor regression in lymphoma xenograft models. *Y:Ln*:Y]Y 2023; 7(Suppl):
  2. Singh, S. P., Dammeijer, F. & Hendriks, R. W. Role of Bruton’s tyrosine kinase in B cells and malignancies. 8pP vGjC]b 2018; 17(1):57.
  3. Tam, C.S, et al. Abstract P686: A Phase 1 first-in-human study of BGB-16673, a Bruton’s tyrosine kinase protein degrader, in patients with B-cell malignancies (trial in progress). *Y:Ln*:Y]Y 2022; 6:582-583.


Please login or register for full access


Already registered?  Login